Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법Incretin-based Treatment for Type 2 Diabetes Mellitus

Other Titles
Incretin-based Treatment for Type 2 Diabetes Mellitus
Authors
김현아김헌성
Issue Date
Jun-2011
Publisher
한국임상약학회
Citation
한국임상약학회지, v.21, no.2, pp 57 - 65
Pages
9
Journal Title
한국임상약학회지
Volume
21
Number
2
Start Page
57
End Page
65
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/147765
ISSN
1226-6051
2508-786X
Abstract
Incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide delay gastric emptying, increasing satiety, and enhance insulin secretion. Two new classes of treatments related to incretin hormones for the management of type 2 diabetes mellitus have emerged: GLP-1 receptor agonists (e.g., exenatide, liraglutide) and the dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin, saxagliptin, vildagliptin, alogliptin), which prevent the degradation of GLP-1. A MEDLINE search was conducted in order to evaluate the efficacy and safety of incretin-based therapies and publications were reviewed. Data from clinical trials indicated incretin-based treatment showed clinically significant reductions in hemoglobin A1c with low risk of hypoglycemia. Weight reductions were observed with GLP-1 receptor agonists where as DPP-4 inhibitors are weight neutral.
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Hyun Ah photo

Kim, Hyun Ah
약학대학 (약학부)
Read more

Altmetrics

Total Views & Downloads

BROWSE